



Please type a plus sign (+) inside this box →

EV519865679US

PTO/SB/08A (08-0)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/822,873
(use as many sheets as necessary)				Filing Date	April 13, 2004
Sheet	1	of	8	First Named Inventor	Henderson et al.
				Group Art Unit	1631
				Examiner Name	
				Attorney Docket Number	CELL-004CON2

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
BP	1	2001-0006633		KIRN, D.	07/05/2001
	2	2001-0053352		YU et al.	12/20/2001
	3	2001-0053768		GREGORY, et al.	12/20/2001
	4	2002-0120117		YU et al.	08/29/2002
	5	2002-0136707		YU et al.	09/26/2002
	6	2002-0192187		MCCLELLAND et al.	12/19/2002
	7	2003-0026792		LAMPARSKI et al.	02/06/2003
	8	2003-0039633		YU et al.	02/27/2003
	9	2003-0068307		YU et al.	04/10/2003
	10	2003-0104624		GORZIGLIA, et al.	02/22/2002
	11	2003-0104625		CHENG et al.	06/05/2003
	12	2003-0152553		LITTLE et al.	08/14/2003
	13	5,112,767		ROY-BURMAN, et al.	05/12/1992
	14	5,302,698		MORINAGA et al.	04/1994
	15	5,324,664		NUNBERG, et al.	06/28/1994
	16	5,358,866		MULLEN et al.	10/25/1994
	17	5,416,017		BURTON et al.	05/16/1995
	18	5,569,667		GROVE et al.	10/1996
	19	5,585,096		MARTUZA et al.	12/17/1996
	20	5,601,818		FREEMAN et al.	02/11/1997
	21	5,624,830		MULLEN et al.	04/29/1997
	22	5,631,236		WOO et al	05/20/1997
	23	5,648,478		HENDERSON	07/1997
	24	5,672,344		KELLEY, et al.	09/30/1997
	25	5,677,178		MCCORMICK, F.	10/14/1997
	26	5,698,443		HENDERSON, et al.	12/16/1997
	27	5,707,618		ARMENTANO, et al.	01/13/1998
	28	5,728,379		MARTUZA et al.	03/17/1998
	29	5,747,469		ROTH, et al.	05/05/1998
	30	5,770,442		WICKHAM et al.	06/23/1998
	31	5,801,029		MCCORMICK, F.	09/01/1998
	32	5,804,407		TAMAOKI et al.	09/08/1998
	33	5,830,686		HENDERSON, D.	11/03/1998
	34	5,837,511		FALCK-PEDERSON, et al.	11/17/1998

Bri / H

11/9/08

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

8

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	HENDERSON et al.
Group Art Unit	1611
Examiner Name	

Attorney Docket Number

CELL-004CON2

DT	35	5,846,945	MCCORMICK, F.	12/08/1998	
	36	5,856,181	MCCORMICK, F.	01/05/1999	
	37	5,871,726	HENDERSON, et al.	02/16/1999	
	38	5,994,128	FALLAUX, et al.	11/30/1999	
	39	5,998,205	HALLENBECK et al.	12/07/1999	
	40	6,051,417	HALLENBECK et al.	04/18/2000	
	41	6,057,299	HENDERSON, D.	05/02/2000	
	42	6,080,578	BISCHOFF, et al.	06/27/2000	
	43	6,133,243	KIRN, D.	10/17/2000	
	44	6,136,792	HENDERSON, D.	10/24/2000	
	45	6,197,293	HENDERSON, et al.	03/06/2001	
	46	6,254,862	LITTLE, et al.	07/03/2001	
	47	6,271,207	CRISTIANO, et al.	08/07/2001	
	48	6,296,845	SAMPSON-JOHANNES, et al.	10/02/2001	
	49	6,297,219	NABEL, et al.	10/02/2001	
	50	6,432,700	HENDERSON, et al.	08/13/2002	
	51	6,436,394	HENDERSON, et al.	08/20/2002	
	52	6,495,130	HENDERSON, et al.	12/17/2002	
	53	6,551,587	HALLENBECK	04/22/2003	
	54	6,585,968	LITTLE et al.	07/01/2003	
	55	6,638,762	CHANG et al.	10/28/2003	
PU	56	6,676,935	HENDERSON et al.	01/13/2004	
PU	57	6,692,736	YU et al.	02/17/04	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Office <sup>3</sup>	Number <sup>4</sup>				
DT	58	WO 90/05180			05/17/1990		
	59	WO 92/03563			03/05/1992		
	60	WO 92/05262			04/02/1992		
	61	WO 94/03594			02/1994		
	62	WO 94/18992			09/01/1994		
	63	WO 94/28152			12/1994		
	64	WO 95/05835			03/02/1995		
	65	WO 95/11984			05/1995		
	66	WO 95/14100			05/1995		
	67	WO 95/14102			05/26/1995		
PU	68	WO 95/19434			07/20/1995		
PU	69	WO 96/14875			05/23/1996		

D LK

W 9/06

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

8

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	1611
Examiner Name	

Attorney Docket Number

CELL-004CON2

B	70	WO 96/16676		06/1996		
	71	WO 96/17053		06/06/1996		
	72	WO 96/18418		06/20/1996		
	73	WO 96/34969		11/07/1996		
	74	WO 97/01358		01/16/1997		
	75	WO 97/04805		02/13/1997		
	76	WO 97/48277		12/24/1997		
	77	WO 98/13508		04/02/1998		
	78	WO 98/27207		06/25/1998		
	79	WO 98/28469		07/02/1998		
	80	WO 98/35028		08/13/1998		
	81	WO 98/39464		09/11/1998		
	82	WO 98/39465		09/11/1998		
	83	WO 98/39466		09/11/1998		
	84	WO 98/39467		09/11/1998		
	85	WO 99/06576		02/11/1999		
	86	WO 99/28469		06/10/1999		
	87	WO 99/55831		11/04/1999		
	88	WO 99/59604		11/25/1999		
	89	WO 00/03029		01/20/2000		
	90	WO 00/15820		03/20/2000		
	91	WO 00/22124		04/20/2000		
	92	WO 00/29599		05/25/2000		
	93	WO 00/31286		06/02/2000		
	94	WO 00/39319		07/06/2000		
	95	WO 00/46355		08/10/2000		
	96	WO 00/47768		08/17/2000		
	97	WO 00/56909		09/28/2000		
	98	WO 00/67576		11/16/2000		
	99	WO 00/70071		11/23/2000		
	100	WO 01/02540		01/11/2001		
	101	WO 01/04282		01/18/2001		
	102	WO 01/04334		01/18/2001		
	103	WO 01/23004		04/05/2001		
	104	WO 01/36650		05/25/2001		
	105	WO 01/72341		10/04/2001		
	106	WO 01/73093		10/04/2001		
	107	WO 02/68627		09/06/2002		
R	108	WO 04/42025		05/21/2004		

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
P - L	109	ABE, M. et al., J. Cell. Physiol. 143:226-231 (1990)	

P - L

V200

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

8

*Complete if Known*

Application Number	10/922,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	161
Examiner Name	
Attorney Docket Number	CELL-004CON2

B	110	ABE, M. et al., Proc. Natl. Sci. Acad. USA, Biochemistry, 90:282-286 (1993)
	111	ARMITAGE, J., Blood 92(12):4491-4508 (December 1998)
	112	AUSUBEL, F.M. et al., Current Protocols in Molecular Biology, Table 7.7.1, Sections 7.7.18-19, Supplement 30 (1987)
	113	AUSUBEL, F.M. et al., Current Protocols in Molecular Biology, Volume I, John Wiley & Sons, Inc., Table of Contents, Supplement 30, 39, pp. iii-xii (1995)
	114	BETT, A. et al., J. of Virology 67(10): 5911-5921 (1993)
	115	BLAESE, R. et al., Eur. J. Cancer 30A: 1190-1193 (August 1994)
	116	BRIDGE, E. et al., J. Virol. 63(2):631-638 (1989)
	117	BRISTOL, et al., Abstract No. P2, presented at The 10 <sup>th</sup> Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002.
	118	BRISTOL, et al., poster at the Keystone Symposia, Basic Aspects of Tumor Immunology, February 17-23, 2003.
	119	BROOKES DE, Prostate 35(1):18-26 (Apr 1, 1998)
	120	BRUDER, et al., Molecular and Cellular Biology 9(11):5143-5153 (Nov 1989).
	121	CHANG, Y. et al., Cold Spring Harbor Gene Therapy Meeting, page 53 (1996)
	122	CHARLESWORTH, C. et al., Urology 49(3):487-493 (1997)
	123	CHIA, et al., Proceedings of the American Association for Cancer Research 43:1098-1099, abstract 5441 (March 2002).
	124	CHIOCCA, E., Nature 2:938-950 (Dec 2002).
	125	CHRIST, et al., Human Gene Therapy, 11:415-427 (Feb 10, 2000).
	126	CLEUTJENS et al., Molecular Endocrinology 11(9):1256-1265, 1997.
	127	CLEUTJENS et al., Molecular Endocrinology 11(2):148-161, 1997
	128	CURIEL, et al., Proceedings of the American Association for Cancer Research 43:662, abstract 3287 (March 2002).
	129	DARSON, M. et al., Urology 49(6):857-862 (1997)
	130	DEMERS, et al., Proceedings of the American Association for Cancer Research 43:663, abstract 3291 (March 2002).
	131	DEWEES, et al., Cancer Research, 61:7464-7472 (Oct 15, 2001)
	132	DORONIN, et al., Journal of Virology, 75(7):3314-3324 (Apr 2001)
	133	DORONIN, et al., Journal of Virology, 74(13):6147-6155 (July 2000)
	134	DUQUE, et al., Cancer Gene Therapy, 6(6):554-563 (1999).
	135	EISELEIN, et al., Cancer Research, 38:3817-3822 (1978)
R	136	ENNIST, D., abstract at the 4 <sup>th</sup> International Conference, The Adjuvant Therapy of Malignant Melanoma, March 15-16, 2002.

7  
2/18

1/10/08

8-

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

8

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	163
Examiner Name	

Attorney Docket Number

CELL-004CON2

B2	137	ENNIST, D., Proceedings of the American Association for Cancer Research 43:1098, abstract 5437 (March 2002).
	138	FALLAUX, et al., Human Gene Therapy, 9:1909-1917 (Sep 1, 1998).
	139	FANG, et al., Journal of Virology, 71(6):4798-4803 (June 1997).
	140	FRIEDMAN et al., Molecular and Cellular Biology, 6(11) 3791-3797, 1986
	141	GANLY, et al., Clinical Cancer Research, 6:798-806 (March 2000)
	142	GOODRUM, F. D., J. Virol. 71(1):548-561 (1997)
	143	GOTOH, A. et al., Proceedings of the American Urological Association 153, 4 Supp. 308A, Abstract No. 320 (1995)
	144	GOTOH, et al., J. Urol. 160(1):220-229 (July 1998)
	145	GRAHAM, F. L., The Journal of General Virology 36(Part 1): 59-72 (1977)
	146	GRAHAM, F, Journal of General Virology, 68:937-940(1987)
	147	GRAND, R., Biochem. J. 241:25-38 (1987)
	148	GREENBERG, N. et al., Molec. Endocrinol. 8(2): 230-239 (1994)
	149	GROOTECLAES, M. et al., Cancer Res. 54:4193-4199 (1994)
	150	HABIB, et al., Human Gene Therapy, 12:219-226 (February 10, 2001)
	151	HALLENBECK, P.L., et al., Human Gene Therapy 10:1721-1733 (1999).
	152	HEARING, et al., Cell, 33:695-703 (1983)
	153	HEISE, et al., Cancer Gene Therapy, 6(6): 499-504 (1999)
	154	HEISE, et al., Clinical Cancer Research, 6:4908-4914 (December 2000)
	155	HEISE, et al., The Journal of Clinical Investigation, 105(7): 847-851 (April 2000)
	156	HERMISTON, T., The Journal of Clinical Investigation, 105(9): 1169-1172 (May 2000)
	157	HITT, M et al., Virology 179:667-678 (1990)
	158	HORWITZ, M., Virology, 279:1-8 (January 5, 2001)
	159	HUBER, B. et al., Adv. Drug. Delivery Reviews 17:279-292 (1995)
	160	HUDSON, L. et al., J. Biol. Chem. 265(8): 4389-4393 (1990)
	161	HUNG MIEN-CHIE et al., Gene 159:65-71 (1995)
	162	IDO AKIO et al., Cancer Res. 55:3105-3109 (1995)
	163	ILAN, et al., Proc. Natl. Acad. Sci. USA, 94:2587-2592 (March 1997)
	164	ISHII SHUNSUKE et al., Proc. Natl. Acad. Sci. USA, Biochemistry 84:4374-4378 (1987)
R	165	JAKUBCZAK, et al., Molecular Therapy, 3(5): abstract 442 (May 2001)

P. LL

11/10/01

29

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	161
Examiner Name	

Sheet

6

of

8

Attorney Docket Number

CELL-004CON2

DT	166	JAKUBCZAK, et al., Molecular Therapy, 5(5): abstract No. 851 (March 2002)
	167	JOHNSON, et al., Proceedings of the American Association for Cancer Research, 43:656, abstract No. 3257 (March 2002)
	168	KANEKO, S. et al., Cancer Research 55:5283-5287 (Nov 1995)
	169	KHURI, et al., Nature Medicine, 6(8): 879-885 (August 2000)
	170	KIRN, D., Gene Therapy, 8:89-98 (January 2001)
	171	KOVARIK, A. et al., J. Biol. Chem. 271(30): 18140-18147 (1996)
	172	KOVARIK, A. et al., J. Biol. Chem. 268(13): 9917-9926 (1993)
	173	KOVESDI, et al., Cell, 45:219-228 (April 25, 1986)
	174	KRAJCSI, et al., Journal of Virology, 70(8): 4904-4913 (August 1996)
	175	KUFE, D. et al., Hybridoma 3(3): 223-232 (1984)
	176	KURIHARA, et al., The Journal of Clinical Investigation, 106(6): 763-771 (September 2000)
	177	KWONG, et al., Chest, 112(5): 1332-1337 (November 1997)
	178	LATHAM JP, Cancer Research 60(2): 334-341 (Jan 15, 2000)
	179	LI, Y. et al. Cancer Research, Vol. 61, No. 17, pp: 6428-6436 (2001).
	180	LI, et al., Proceedings of the American Association for Cancer Research, 43:858, abstract No. 4251 (March 2002)
	181	LUNDWALL, A. et al., Biochim. Biophys. Res. Commun. 161(3): 1151-1159 (1989)
	182	LUNDY, J. et al., Breast Cancer Res. Treat. 5:269-276 (1985)
	183	LYONS, R., ASM Gene Therapy Conference, February 28, 2003, Banff, Alberta CA: oral presentation presented February 28, 2003
	184	MABJEEESH, et al., Endocrine-Related Cancer, 9:115-139 (June 2002)
	185	MANOME, et al., Cancer Research, 54(20): 5408-5413 (October 15, 1994)
	186	MILLER, et al., Human Gene Therapy, 8:803-815 (May 1, 1997).
	187	MORRIS, B., Clin. Exp. Pharm. Physiol. 16:345-351 (1989)
	188	MURTHA, P. et al., Biochem. 32(25): 6459-6464 (1993)
	189	NEMUNAITIS, et al., Cancer Research, 60:6359-6366 (November 15, 2000)
	190	OSAKI, T. et al., Cancer Research 54:5258-5261 (Oct 1994)
	191	PAIELLI, et al., Molecular Therapy, 1(3): 263-274 (March 2000)
↓	192	PANG, S. et al., Human Gene Therapy 6(11): 1417-1426 (Nov 1995)
PL	193	PECORA, et al., Journal of Clinical Oncology, 20(9): 2251-2266 (May 1, 2002)

P 1/1

W 8/8/04

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

8

*Complete if Known*

Application Number	10/922,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	16
Examiner Name	

Attorney Docket Number

CELL-004CON2

194	PETER, et al., Abstract No. P78, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002
195	RAMACHANDRA, et al., Nature Biotechnology, 19:1035-1041 (November 2001)
196	RENNIE, P. et al., Molec. Endocrinol. 7(1): 23-36 (1993)
197	RICCIO, A. et al., Nucleic Acids Res. 13(8): 2759-2771 (1985)
198	RICHARDS, C. et al., DNA Sequence-J. DNA Sequencing and Mapping, 4:185-196 (1993)
199	RICHARDS, C. et al., Human Gene Therapy 6:881-893 (1995)
200	RIEGMAN, P. et al., Molec. Endocrinol. 5(12):1921-1930 (1991)
201	RIES, et al., British Journal of Cancer, 86:5-11 (January 7, 2002)
202	RODRIGUEZ, R. et al., Cancer Res. 57:2559-2563 (1997)
203	RUSSELL, S., Eur. J. Cancer 30A: 1165-1171 (August 1994)
204	RUSSELL, W., Journal of General Virology, 81:2573-2604 (November 2000)
205	RYAN, et al., Eleventh International Conference on Gene Therapy of Cancer, San Diego, CA, December 12-14, 2002, 10(Suppl. 1): abstract No. 036
206	RYAN, et al., Abstract No. Or34, presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, October 13-16, 2002
207	SAMBROOK, J. et al., Cold Spring Harbor Laboratory Press, Table of Contents, pp. xi-xxxviii (1989)
208	SAUTHOFF, et al., Human Gene Therapy, 11:379-388 (February 10, 2000)
209	SCHEDLICH, L. et al., DNA 6(5): 429-437 (1987)
210	SCHREWE, H. et al., Mol. Cell. Biol. 10(6): 2738-2748 (1990)
211	SCHURR, E. et al., J. Biol. Chem. 271:7043-7051 (1996)
212	SHI, et al., Human Gene Therapy, 8:403-410 (March 1, 1997)
213	STEINWAERDER, et al., Gene Therapy, 7(7): 556-567 (April 2000)
214	STEWART, et al., Molecular Therapy, 5(5): abstract No. 53 (May 2002)
215	SWAMINATHAN, S., Curr. Topics in Microbiol. and Immunol. 199 Part 3:177-193 (1995)
216	TAL, M. et al., Mol. Cell. Biol. 7(7): 2597-2601 (1987)
217	TANEJA, S. et al., Proceedings of the American Association for Cancer Research 35:page 375, Abstract No. 2236 (1994)
208	TOLLEFSON, A. et al., J. Virol. 70(4): 2296-2306 (April 1996)
209	UENO, et al., Oncogene, 15:953-960 (1997)
220	VASSAUX, et al., Gene Therapy, 6:1192-1197 (1999)
221	VILE, et al., Cancer Gene Therapy, 9:1062-1067 (December 2002)

P.M. Miller

1/18/04

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

8

*Complete if Known*

Application Number	10/822,873
Filing Date	April 13, 2004
First Named Inventor	Henderson et al.
Group Art Unit	117
Examiner Name	

Sheet	8	of	8	Attorney Docket Number	CELL-004CON2
-------	---	----	---	------------------------	--------------

P21	222	WEN, et al., Proceedings of the American Association for Cancer Research, 43:1098, abstract No. 5440 (March 2002)	11
	223	WOLD, et al., Trends in Microbiology, 2(11): 437-443 (November 1994)	
	224	WOLD, et al., Curr. Top. Microbiol. Immunol., 199:237-274	
	225	WOLD, Virology, 184:1-8 (1991)	
	226	WOLD, et al., Current Opinion in Immunology, 11:380-386 (1999)	
	227	YOHN, et al., Journal of National Cancer Institute, 41:523-529 (1968)	
	228	YOUNG, C. et al., Biochem. 31(3): 818-824 (1992)	
	229	YU et al., Cancer Gene Therapy 8(9): 628-635 (Sep 2001)	
	230	YU H, et al., Cancer Research 55(10): 2104-2110 (May 15, 1995)	
	231	YU, DC et al. Cancer Research, 59(7): 1498-1504 (1999).	
	232	YU, et al., Cancer Research, 59:4200-4203 (September 1, 1999)	
	233	YU, et al., Cancer Research, 61:517-525 (January 15, 2001)	
	234	ZHANG, et al., Proceedings of the American Association for Cancer Research, 43:597, abstract No. 2955 (March 2002)	
	235	ZHANG, J. et al., Nucleic Acids Res. 25(15) 3143-3150 (1997)	
	236	ZHOU, ZHONG-XUN et al., Recent Progress in Hormone Research 49:249-274 (1994)	
P21	237	ZHU, et al., Molecular Therapy, 5(5):abstract No. 317 (May 2002)	

Examiner Signature

D. A. d. l.

Date Considered

11/9/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.